No connection

Search Results

ABBV vs BGM

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
BGM
BGM Group Ltd.
BEARISH
Price
$3.72
Market Cap
$746.3M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
BGM
--
Forward P/E
ABBV
15.42
BGM
--
P/B Ratio
ABBV
-146.66
BGM
2.01
P/S Ratio
ABBV
6.5
BGM
24.99
EV/EBITDA
ABBV
15.27
BGM
-29.15

Profitability

Gross Margin
ABBV
71.46%
BGM
2.92%
Operating Margin
ABBV
35.5%
BGM
-5.41%
Profit Margin
ABBV
4.0%
BGM
-26.32%
ROE
ABBV
137.96%
BGM
-16.52%
ROA
ABBV
9.59%
BGM
-3.84%

Growth

Revenue Growth
ABBV
9.1%
BGM
-56.9%
Earnings Growth
ABBV
-88.7%
BGM
0.0%

Financial Health

Debt/Equity
ABBV
--
BGM
0.0
Current Ratio
ABBV
0.72
BGM
7.05
Quick Ratio
ABBV
0.47
BGM
5.94

Dividends

Dividend Yield
ABBV
3.05%
BGM
--
Payout Ratio
ABBV
490.15%
BGM
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
BGM BEARISH

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score and negative profitability metrics raise concerns. The company is unprofitable with a -26.32% profit margin, -5.41% operating margin, and negative ROE and ROA, while revenue has collapsed by 56.90% year-over-year. Valuation multiples are extremely high with a Price/Sales ratio of 24.99 despite deteriorating fundamentals, and the stock has lost 90.8% of its value over five years. Although the balance sheet shows no debt and strong liquidity ratios, the lack of earnings, cash flow data, and analyst coverage suggests high uncertainty and limited investor confidence.

Strengths
Piotroski F-Score of 6/9 indicates stable financial health relative to distressed peers
Exceptionally strong liquidity with a Current Ratio of 7.05 and Quick Ratio of 5.94
Zero debt (Debt/Equity = 0.00), reducing solvency risk
Risks
Severe profitability issues: -26.32% profit margin and -16.52% ROE
Catastrophic revenue decline of -56.90% YoY, far worse than peer average
Price/Sales of 24.99 is extremely high for a shrinking, unprofitable company

Compare Another Pair

ABBV vs BGM: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and BGM Group Ltd. (BGM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile